. Author manuscript; available in PMC: 2018 Feb 6.

Published in final edited form as: J Biopharm Stat. 2017 Feb 6;27(3):477–494. doi: 10.1080/10543406.2017.1289952

Table 3.

Case Study 1: Probability of selecting each dose as the maximum tolerated dose (MTD). Results for the true MTD are in bold.

	Dose 8	Dose 9	Dose^* 10	Dose 11
Assumed DLT probabilities used in simulations	0	0.15	0.25	0.35
‘3+3’ design (N = 34)^**	0.19	0.33	0.29	0.19
CRM (N = 54)	0	0.19	0.63	0.18
CRM (N = 32)	0	0.22	0.54	0.24

MTD declared by the original trial.

^**

Average sample size obtained from 2,000 simulated trials.

CRM: Continual Reassessment Method